If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Jaypirca ® (pirtobrutinib) tablets
50 mg,100 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What should be monitored in patients treated with Jaypirca® (pirtobrutinib)?
Monitor patients on pirtobrutinib for infections, hemorrhage, cytopenia, atrial fibrillation and atrial flutter, hepatotoxicity, and the development of second primary malignancies.
Monitoring During Pirtobrutinib Treatment
Special Precautions During Pirtobrutinib Treatment shows special precautions during pirtobrutinib treatment. Further details on monitoring are provided in the sections below the image.
Infections
Patients treated with pirtobrutinib should be monitored for signs and symptoms of infections. The signs and symptoms should be evaluated and treated promptly as medically appropriate. Patients should be counseled to report any signs or symptoms of infection (eg, fever, chills, and weakness).1
Prophylaxis, including vaccinations and antimicrobial prophylaxis, should be considered for patients who are at an increased risk for infections, including opportunistic infections.1
Hemorrhage
Patients treated with pirtobrutinib should be monitored for signs of bleeding.1
The risks and benefits of withholding pirtobrutinib treatment for 3-7 days pre-surgery and post-surgery depending upon the type of surgery and risk of bleeding should be considered during treatment with pirtobrutinib. The benefit-risk should also be considered in the event of co-administration of antithrombotic agents with pirtobrutinib.1
Cytopenias
For patients treated with pirtobrutinib, complete blood counts should be monitored regularly during treatment.1
Cardiac Arrhythmias
Patients treated with pirtobrutinib should be monitored for signs and symptoms of arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea) and managed appropriately. Patients should be counseled to report any signs of palpitations, dizziness, fainting, chest discomfort, and shortness of breath while on treatment.1
Hepatotoxicity
Evaluate bilirubin and transaminases at baseline and throughout treatment with pirtobrutinib. For patients who develop abnormal liver tests, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity.1
Second Primary Malignancies
Patients treated with pirtobrutinib should be monitored for the development of second primary malignancies. Patients should be counseled to use appropriate sun protection.1
Enclosed Prescribing Information
Reference
The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).
1Jaypirca [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
Date of Last Review: October 09, 2025